FDA EXTENDS DATE FOR POLYPHENON E OINTMENT REVIEW FOR BRADLEY

Friday, Bradley Pharmaceuticals Inc., a specialty pharmaceutical company, announced that it was advised by Polyphenon E ointment licensor MediGene AG that the Food and Drug Administration extended its deadline to complete a review of the product as a treatment for external genital warts. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/294925/)